Sep 28, 2022 | 2022, Investors, Press Releases
More detailsSep 28, 2022 | 2022, Investors, Press Releases
More detailsSep 28, 2022 | 2022, Investors, Press Releases
Philogen’s management team will hold a webinar on 29 September 2022 at 10:00 ET / 15:00 BST / 16:00 CEST following an R&D Update. Prof. Dr. Dario Neri, Chief Executive Officer, Dr. Laura Baldi, Chief Financial Officer, and Dr. Emanuele Puca, Head of Investor...Sep 26, 2022 | 2022, Investors, Press Releases
More detailsSep 19, 2022 | 2022, Investors, Press Releases
More detailsSep 15, 2022 | 2022, Press Releases, Scientific
The study shows selective tumor uptake of IL12-7NP2 and potent antitumor activity as single agent and in combination with immune checkpoint inhibitors. The product is well tolerated when administered to non-human primates. More details
Recent Comments